NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects Drug Industry Remove constraint Subjects: Drug Industry

Search Results

1. Drug supply chain security: dispensers received most tracing information

2. Pharmacogenomics: a primer for policymakers

3. Drug and device manufacturer communications with payors, formulary committees, and similar entities: questions and answers : guidance for industry and review staff

8. Drugs resources: manufacturers, importers, processors : biologicals, botanicals, containers, fish liver oils, narcotics, hormones and glandular substances, medicinal chemicals, surgical dressings

9. Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to Congressional requesters

13. Pharmaceuticals and insecticides at I.G. Farben plants Elberfeld and Leverkusen

21. Pharmaceutical targets: Nordmark Werke - Utersen, Germany, I.G. Farben - Leverkusen, Germany, I.G. Farben - Hochst, Germany, Behringwerke - Marburg, Germany, E. Merck - Darmstadt, Germany

22. Pharmaceuticals and insecticides at the I.G. Farbenindustrie plant Höchst A. Main, 10-11 April 1945

24. The prescription drug safety net: access to pharmaceuticals for the uninsured

25. Best practices for communication between IND sponsors and FDA during drug development: guidance for industry and review staff : good review practice

41. Good manufacturing practice considerations for responding to COVID-19 infection in employees in drug and biological products manufacturing

44. COVID-19 public health emergency: general considerations for pre-IND meeting requests for COVID-19 related drugs and biological products : guidance for industry and investigators

45. Wholesale distributor verification requirement for saleable returned drug product and dispenser verification requirements when investigating a suspect or illegitimate product: compliance policies

48. Review timelines for applicant responses to complete response letters when a facility assessment is needed during the COVID-19 public health emergency

49. Remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities during the COVID-19 public health emergency